Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
October 8th, 2007
Knopp Neurosciences Inc. ("Knopp") announced the initiation of a Phase 1 clinical trial of KNS-760704, a small molecule therapy in development for the treatment of amyotrophic lateral sclerosis (ALS). This randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers is being closely followed by a multiple ascending dose study in healthy subjects. Both studies are designed to evaluate the safety, tolerability and pharmacokinetics of KNS-760704 in human subjects. "The initiation of Phase 1 represents a significant milestone in Knopp's efforts to develop a safe and effective therapy for a serious unmet medical need,"...
Source: Biotech Business Week (2007-10-08)
|
